pralsetinib (Gavreto)

Indications

• adults with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test

* detected by an FDA approved test

Contraindications

• pregnancy

Dosage

• 400 mg orally once daily on an empty stomach

* no food intake for at least 2 hours before * at least 1 hour after

Capsules: 100 mg

Adverse effects

• >25%
  • fatigue, constipation, musculoskeletal pain, hypertension
• laboratory abnormalities (>2%)
  • lymphopenia, neutropenis, hypophosphatemisa, anemia, hyponatremia, hypocalcemia, increased serum ALT
• warnings
  • interstitial lung disease
  • hepatotoxicity
  • hemorrhage
  • hypertension
  • impaired wound healing

• drug adverse effects of tyrosine kinase inhibitor(s)

Drug interactions

• strong CYP3A inducers &/or inhibitors; void coadministration.

Mechanism of action

• tyrosine kinase inhibitor of wild-type RET & oncogenic RET fusions

More general terms

• small inhibitory antineoplastic agent (ib drug)
• tyrosine kinase inhibitor